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Abstract
Background: Activation of the sympathetic nervous system (SNS) in response to chronic
biobehavioral stress results in high levels of catecholamines and persistent activation of
adrenergic signaling, which promotes tumor growth and progression. However it is
unknown how catecholamine levels within the tumor exceed systemic levels in circulation.
I hypothesized that neo‐innervation of tumors is required for stress‐mediated effects on
tumor growth.
Results: First, I examined whether sympathetic nerves are present in human ovarian
cancer samples as well as orthotopic ovarian cancer models. Immunohistochemical (IHC)
staining for neurofilament revealed that catecholaminergic neurons are present within
tumor tissue. In order to determine whether chronic stress affects the density of nerves in
the tumor, I utilized an orthotopic mouse model of ovarian cancer that was exposed to
daily restraint stress. IHC analysis revealed that nerve density in tumors increased by more
than three‐fold in stressed animals versus non‐stressed controls. IHC analysis suggested
that this results from both recruitment of existing neurons (axonogenesis) as well as new
neuron formation (neurogenesis) within the tumor. To determine how tumors are
recruiting nerve growth, I utilized a PCR array analysis of 84 nerve growth related genes
and their receptors, which showed that stimulation of the SKOV3 ovarian cancer cell line
with norepinephrine (NE) leads to increased expression of several neurotrophins,
including brain‐derived neurotrophic factor (BDNF). Neurite extension assays showed that
media conditioned by ovarian cancer cell lines is capable of inducing neurite outgrowth in
differentiated neuron‐like PC12 cells, and NE treatment of cancer cells potentiates this
effect. Norepinephrine‐induced neurite extension was abolished after BDNF silencing by
siRNA, suggesting that BDNF is critical to tumor cell‐induced nerve growth. in vivo BDNF
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inhibition resulted in complete abrogation of stress‐induced increases in tumor weight and
nerve density, as well as downstream markers of stress.
Discussion: These studies indicate that adrenergic signalling induced by chronic stress
promotes neo‐innervation in the tumor microenvironment. This results in a mutually
beneficial relationship between the tumor cells and neurons. This work is crucial for
providing a link between chronic stress and its effects on the tumor and its
microenvironment. The data shown here aims to open new venues that can be used in
development of therapies designed to block the stress effects on tumor growth.
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Introduction

(Parts of this section were adapted with permission in part from Allen JK, et al, Stress and Cancer,
from the M.D. Anderson Handbook of Psychosocial Oncology, McGraw‐Hill, 2010)
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1.

Rationale and Significance
Modern science has demonstrated that biobehavioral factors can affect

disease states. This interaction was coined the “mind‐body” model of illness by
psychiatrist George Engel (1). Since then, experimental and clinical evidence has
shown that psychological factors can affect several types of diseases, including
cardiovascular disease and cancer. Altered mental and physical states, such as
depression or stress, activate the sympathetic nervous system and hypothalamic‐
pituitary‐adrenal axis to cause release of hormones, including catecholamines.
Recent evidence has shown that catecholamines are capable of promoting tumor
growth and progression (2) through increases in tumoral catecholamine levels (3).
We sought to find a link between chronic stress and the high levels of
catecholamines seen within tumor tissue. Catecholamines may be released into
circulation by the adrenal gland or locally by sympathetic nerve endings.

I

hypothesized that sympathetic neurons within the tumor would be responsible and
that chronic stress would be capable of inducing growth of these neurons into the
tumor.
stressed

My work demonstrates 1) nerve density in tumors from chronically
animals

is

increased

compared

to

non‐stressed

controls;

2)

Norepinephrine signals through the β3‐arenergic receptor to stimulate BDNF
production in tumor cells which is then responsible for promoting nerve growth
into the tumor; 3) high nerve density is associated with high BDNF expression and
poor outcome in ovarian cancer patients. Together these data represent the first
demonstration that tumors are capable of promoting neo‐innervation. It also
demonstrates that neo‐innervation of tumors is required for chronic stress‐
2

mediated tumor progression. This work provides evidence that BDNF may be a
viable therapeutic target in chronically stressed patients in order to block the
deleterious effects of chronic stress on patient outcome.

2.

Historical views of biobehavioral impact on disease
In 1977 Engel published a seminal article in Science proposing what he

called the biopsychosocial model of human disease. In this model, he theorized that
human disease is affected not only by biological factors, but also by psychological
and social factors. Though his study is seen as a turning point in the field, the idea
that psychosocial factors might influence disease states had been around for
centuries. In Roman times the philosopher Galen noted that “melancholy” women
were more likely to develop cancer (4). Alexandre Dumas’ physician wrote that he
thought the author’s stomach cancer was due to the agitations of a public lifestyle
(5). Dogen, a Buddhist monk, discussed in his Shobogenzo that people who tend
towards a less complicated lifestyle are less likely to be sick.

In more modern research, scientists have begun to elucidate the
mechanisms behind these observations. These studies have given us a thorough
understanding of the systems our bodies use to cope with stress, yet have only
begun to elucidate how and why these mechanisms can benefit, or sometimes be
detrimental to, our health. More studies are necessary to further illuminate the
mechanism of how stress affects disease.

3

3.

The Stress Response
In a healthy, non‐stressed individual, the body’s homeostasis is

maintained through a balance between virtually every system in the body. Each
system runs at counterbalance to the others at normal basal levels to keep the body
healthy and functional.

As shown in Figure 1A, the sympathetic and

parasympathetic nervous systems (SNS and PSNS, respectively) act as opposites to
regulate many body functions. Stress, however, causes a disruption in this balance.
The catecholamines of the sympathetic nervous system overbalance and cause
hyperactivation of critical systems, vasoconstriction, and overall heighten the
body’s capability of dealing with a perceived stressor. In the case of chronic stress,
the body remains in this constant state of hyper‐activation and awareness, and
eventually results in a multitude of health issues

Stress is an extremely complex process that has widespread and
diverse effects throughout the body, ranging from cardiovascular effects to changes
in gastrointestinal function and immunity. Once the body detects a stressor, the
central nervous system (CNS) activates both the autonomic nervous system (ANS)
and the hypothalamic‐pituitary‐adrenal axis (HPA). Stimulation of the ANS results
in activation of the sympathetic nervous system (SNS) and subsequent release of
catecholamines. Among other functions, Norepinephrine (NE) and epinephrine
control blood pressure and heart rate. They act as vaso‐constrictors, increasing
blood pressure, and increasing blood flow to organs critical to the fight or flight
4

stress response.

The third catecholamine, dopamine, is involved in learning,

sociability, and promoting reward‐seeking behavior (6). Its release is used to
control levels of prolactin, which has numerous functions in the body, from
reproduction to neurological function and immunity (7).

Activation of the HPA axis causes release of corticotrophin releasing
hormone (CRH) from the hypothalamus, setting off a cascade that results in release
of glucocorticoids from the adrenal gland (Figure 1B).
hormones are found on virtually every cell type.

Receptors for these

In normal physiology,

glucocorticoids are responsible for regulating immunity, cardiovascular function,
and metabolism, among others (8, 9). Under stress conditions these hormones are
responsible for the defeat/withdrawal response. Under chronic stress conditions
they cause prolonged inhibition of CRH and subsequent inhibition of immunity.

Stress responses are highly adaptive systems that affect not only
physiological changes, but also behavioral and neurological systems. Combined,
these changes make up the collective “stress syndrome.” First, the body prepares
for its best chance of survival by shutting down physiological functions that are not
immediately deemed essential, and reroutes those resources to more critical
functions. For example, following detection of a stressor the body slows digestion
and growth as well as inhibits immune function and stalls reproductive urges.
Conversely, it increases cardiac output, respiratory rate, and energy production.

5

A.

B.

Figure 1. Systems involved in the stress response. A. Counterbalancing
effects of the Parasympathetic and Sympathetic Nervous Systems. B.
Activation of the HPA axis leading to cortisol secretion.
(Figures used with permission from 158‐159)
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Behaviorally, the individual becomes more alert, focused, and has increased mental
faculties for processing his/her surroundings and circumstances (10).

4.

Acute versus chronic stress
It is important to distinguish between the types of stress the body can

experience.

Although stressors can be physical, mental, emotional, social, or

biological, a critical distinction is whether the stress is acute or chronic. Acute
stressors are short‐lived, infrequent, and beneficial to the body. A good example
would be an individual giving a public speech or taking a test. Following an acute
stressor the body prepares by releasing catecholamines and glucocorticoids to
increase blood flow and prepare the body to cope. Once the stressor is removed,
the stress response systems return to baseline and normal function resumes.

On the other hand, chronic stressors recur frequently or are sustained
over long periods of time, typically from months to years. Good examples of
chronic stressors are depression, chronic fatigue, a feeling of isolation or poor
social support, or even the daily strain of a stressful job. While chronic stressors
activate the same pathways as acute stressors, their continual or persistent nature
does not allow these systems time to shut off, leaving the body in a constant state of
overdrive. This continual response causes a prolonged disruption of the body’s
homeostasis as it attempts to cope.

Over time this increases risk of several

diseases, most particularly cardiovascular disease, and has been associated with
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disruptions in metabolism, reproduction, immune activity, and even cancer
initiation (11‐13).

5.

Chronic stress impacts on disease

A.

Chronic stress and Cardiovascular disease
Effects of chronic stress on the cardiovascular system are perhaps the

most well‐studied and characterized. This link has been investigated for more than
six decades, and has shown from virtually every angle that psychological and
biobehavioral factors play a major role in promoting cardiovascular disease. These
studies show that psychological factors can cause myocardial infarctions, coronary
heart disease, hypertension, atherosclerosis, and other cardiovascular health issues
(14). For example, studies have demonstrated that even short periods of chronic
stress can increase risk of cardiovascular problems decades later (15). Large
epidemiological studies have correlated feelings of irritability or anxiety with
increased incidence of myocardial infarctions (16).

Effects of chronic stress on risk of cardiovascular disease are primary a
result of increased levels of cortisol and catecholamines. Catecholamines signal
through adrenergic receptors (ARs), primarily the β‐family of adrenergic receptors
(ADRB) (see section 7B below). As a result, many patients with cardiovascular
disease are treated with β‐blockers, a class of drugs that inhibits catecholaminergic
activation of β‐ARs, resulting in lower blood pressure and heart rate.
8

B.

Chronic stress and immunity
Chronic stress effects on the immune system are mediated primarily

through activation of the HPA axis and release of glucocorticoids, as well as some
control through the ANS and catecholamines. Several studies have demonstrated
interactions between the CNS, endocrine, and immune systems, and suggest that
disruption to one system will have subsequent effects on all.

The dual nature of glucocorticoids in acute versus chronic stress is
highly pertinent to immune function. Normal physiologic levels of glucocorticoids
are immunoregulatory, maintaining normal immune surveillance. Chronic stress
significantly increases levels of glucocorticoids, at which point they become
immunosuppressive.

Within the immune system T and B cell, neutrophils,

monocytes, and macrophages all carry glucocorticoid receptors. This allows for
chronic stress to disrupt both cellular and humoral immune responses, such as
inhibiting inflammation, causing a shift in the balance between Th1 and Th2
cytokines, and causing antigen‐presenting cells to cease production of IL‐12, all of
which are important for immune adaptation (17,18). High levels of glucocorticoids
can also cause apoptosis in monocytes, macrophages, and T lymphocytes (19).

C.

Chronic stress and the central nervous system
Chronic stress can also have significant effects on neurological function.

Specific brain regions (notably the hippocampus) express high densities of
glucocorticoid receptors. Chronic stress levels of glucocorticoids can therefore
9

have very prominent effects on memory, both through interfering with new
memory formation (20,21), as well as in preventing access to existing memories.
For example, hippocampal function is significantly reduced following chronic
stress, and several studies support that this is due to dendritic retraction of CA3
neurons, ultimately resulting in impaired special memory (22).

Additionally,

chronic stress is known to impair neurogenesis in the dentate gyrus region of the
hippocampus, thereby impairing new memory formation and increasing anxiety‐
like responses (23).

6.

Chronic stress and cancer (Figure 2)
More recent studies have demonstrated that chronic stress has a

pronounced impact on virtually every facet of cancer, from playing a role in cancer
initiation to promoting tumor growth and metastasis through several mechanisms.
These studies have looked at both animal models of chronic stress as well as human
clinical data.

A.

Animal models of chronic stress
Several different methods have been used to mimic the effects of

psychosocial stress in laboratory animals. Methods have included swim stress,
hypothermia, rotation, restraint, social isolation, and social domination. Our group
routinely uses the restraint stress model. Studies have demonstrated that physical
restraint stress causes modulations in levels of both catecholamines and

10

Figure 2. Chronic stress effects on tumor progression. Stress
promotes tumor progression through activation of the autonomic nervous
system and the hypothalamic‐pituitary‐adrenal (HPA) axis

(Figure used with permission from (156))
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glucocorticoids (2, 24). We have found that chronic restraint stress increased
tumor growth, and exhibited higher tumor levels of catecholamines and
glucocorticoids, suggesting that this model activates both the HPA axis and
sympathetic nervous system, and therefore functions as a good model for
mimicking chronic psychological stress in humans (2, 24).

B.

Chronic stress and cancer initiation
Human tumorigenesis is a complex, multistep process. Hanahan and

Weinberg postulated that six steps are required for transformation of cells: self‐
sufficiency in growth signals, insensitivity to antigrowth (growth inhibitory)
signals, evasion of programmed cell death (apoptosis), limitless replicative
potential, sustained angiogenesis, and tissue invasion and metastasis (25).
Evidence that chronic stress may play a role in promoting this transformation is,
however, difficult to reconcile due to often contradictory results. Two separate
clinical studies have been performed on women following identification of a
suspicious lesion, and prior to diagnosis by biopsy. The first of these studies found
a significant correlation between malignant lesions and the occurrence of at least
one major stressful life event in the previous 5 years (26). Conversely the second
study concluded that day‐to‐day stress actually decreased risk of breast cancer by
as much as 40% (27). The confounding results demonstrated by these studies as
well as others may be the result of variations in statistical analysis, differences in
methods of determining stress, and the inability to differentiate whether stress is
actually causing cancer or whether its role is more important for progression of a
12

tumor to a malignant lesion. Additional difficulties arise in that these studies are all
epidemiological, retrospective studies. A long‐term longitudinal epidemiological
study may be needed to more effectively elucidate the involvement that chronic
stress has on tumor initiation; however no such study has been done, most likely
due to restraints such as feasibility and cost. It is also difficult due to the fact that
there are very few ways of mimicking this process in pre‐clinical models, and
similar restraints exist to prevent the feasibility of any such model. To date, very
few studies have demonstrated solid biological mechanisms that may suggest
chronic stress can initiate tumor formation, though those that exist seem to indicate
it is through enhancement of DNA damage. Glaser et al demonstrated that stress
can impair DNA repair through downregulation of the ciritcal DNA repair enzyme
Methyltransferase (28). Hara et al also demonstrated that stress enhances DNA
damage through activation of β‐arrestin‐1 (29).

7.

Stress and cancer progression
In the last few decades, there have been significant data supporting

chronic stress effects on cancer progression from both preclinical and clinical
settings. Clinically, chronic stress has been associated with poorer outcome in
cancer patients (30‐34). Preclinical evidence has demonstrated that chronic stress
can promote cancer progression through increased angiogenesis, invasion, and
migration leading to metastasis, cell survival, and immune escape.

13

A.

Stress, Immunity, and cancer progression
There are a significant amount of data supporting the role of chronic

stress in suppressing the immune system to allow tumors to progress.

As

previously mentioned, chronic stress causes a shift in immune function. Stress
hormones inhibit cellular, or Th1, immunity, allowing tumor cells to evade
surveillance. Stress inhibits release of pro‐inflammatory cytokines, impairing
maturation and tumor eliminating capacity of NK cells, T cells, and macrophages
(35). Epinephrine and prostaglandin, two hormones that increase following chronic
stress, were found to promote progression of leukemia by suppressing NK cell
activity (36). Clinically, patients with poorer social support had lower levels of anti‐
tumorigenic cytokines and increased IL‐4, which indicates poorer immune‐
mediated clearance of tumor cells (37). Additionally, tumor‐infiltrating leukocytes
(TILs) demonstrate increased type‐2 immune response, which is generally
considered pro‐tumorigenic (38‐41). Poor social support has also been seen to
reduce NK cell activity (42‐43). Catecholamines have been shown to have a
significant effect directly on immune activity. Inhibition of SNS activity promotes
adaptive immunity through increases in Th1 immunity (44). Cunnick et al
demonstrated that adrenalectomy recovered T‐cell responses previously inhibited
by stress (45).

B.

Stress and adrenergic signaling in cancer
Effects of catecholamines are mediated through adrenergic receptors

(ARs). This family of 7‐transmembrane G‐coupled receptors consists of a total of 8
14

receptors divided into α and β sub‐families (46). Several studies have found these
receptors to be expressed on a variety of tumor types, with increased expression
found in several cancers such as oral, liver, and colon (47‐50). G‐coupled receptors
act as molecular switches to control a diverse array of downstream signaling
pathways, and have been found to contribute to several pathways of tumor
initiation and progression. These receptors have a dichotic function, acting
something like on/off switches for their downstream signaling. Binding of the Gs
subunit results in activation of downstream pathways, while binding of the Gi
subunit inhibits signaling.

When members of the ADRB family are activated, they initiate
downstream signaling through the cAMP/PKA and Epac signaling pathways.
Downstream of PKA signaling can activate the cAMP Response Element Binding
(CREB) protein which can activate a wide array of human genes, many of which are
crucial to tumor growth and migration (51‐52). Signaling through Epac (Exchange
Protein activated by Adenylyl Cyclase) activates the MAP Kinase signaling pathway,
which is well known to have potent effects promoting tumor proliferation.

C.

Neuroendocrine effects on tumor cell proliferation
Cell growth, proliferation, and survival are controlled through a

balance between positive and negative signals. Stress hormones can interfere with
this balance (53). Studies have shown conflicting evidence for neuroendocrine
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impact on tumor cell proliferation. For instance, several studies have found that
adrenergic activation inhibits tumor cell proliferation, while others suggest it may
enhance cell proliferation. One group found that ADRB2 signaling was required for
pancreatic cell survival, and that blockade of ADRB2 induced cell apoptosis through
the NFkB pathway (54). Conversely, another group found that NE treatment of
breast cancer cells stimulated proliferation through an α2‐AR specific pathway, and
that use of an ADRB agonist countered this effect and decreased proliferation (55).
Yet another group found that NE treatment inhibited proliferation of mouse
chondrocytes through the ADRB2 receptor (56). Perhaps one could argue that
response is simply cell‐type specific, and depends largely on which adrenergic
receptor family members are expressed on the cell.

Although the impact of adrenergic activation on proliferation is
conflicting, the vast majority of studies all agree that chronic stress promotes tumor
growth. This begs the question, if adrenergic activation is not promoting growth
through cell proliferation, then which mechanisms are being modulated? Studies
from our group and others show that it is in fact through promoting cell survival
and inhibition of apoptosis.

D.

Adrenergic influences on tumor cell survival
Tumor cells must adhere to extracellular matrix (ECM) compounds in

order to metastasize and to avoid anoikis (Greek for “homelessness”). As previously
16

mentioned, activation of adrenergic receptors causes downstream activation of
cAMP signaling, which controls cellular adhesion through PKA‐mediated activation
of RhoA and Rac (57). Additionally, activation of Epac downstream of β‐ARs has
been found to increase ovarian cancer cell adhesion (58). Focal Adhesion Kinase
(FAK) aids cell adhesion to the ECM. Non‐transformed cells will undergo apoptosis
when their connection to the ECM is broken, due to a process called anoikis.
Norepinephrine increases FAK activation to increase tumor cell adhesion and
survival. Blocking FAK in vivo inhibits chronic stress effects on tumor growth by
failing to protect cells from anoikis (59).

Sastry et al also demonstrated that NE acts through the β2‐AR to
protect cancer cells from apoptosis (60).

Their studies demonstrated that

activation of PKA resulted in downstream phosphorylation of BAD at Ser112, the site
thought to have primary control over antiapoptotic signaling downstream of BAD.
Adrenergic activation is also thought to convey chemoresistance in some types of
cancers (61‐62). Studies in both breast and colon cancer have demonstrated that α‐
adrenergic receptor activation increased expression of MDR1, a gene long known to
convey chemoresistance to tumor cells.

E.

Stress and metastasis
In the vast majority of cases, patients suffering from cancer do not die as a

result of their primary tumor, but much more commonly as a result of metastatic
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lesions. It is therefore important to understand how a tumor metastasizes, and
how chronic stress can promote this process. Metastasis is a complex process in
which the cells must sequentially gain several characteristics or the cascade fails
(63) (Figure 3). First, a developing tumor must develop a blood supply, as nutrients
and oxygen from the bloodstream are only capable of diffusing <1 mm through
tissues. This also provides a direct route for metastasis of cancer cells to other
locations in the body. Secondly, tumor cells must be capable of detaching from the
main tumor, secreting enzymes which break down the basement membrane and
allow embolization into the blood stream. Once the cell becomes entrapped in a
capillary bed, it must then be capable of extravasation from the blood stream and
begin to grow in the new tissue bed, at which point the cycle begins again, and the
new tumor must establish its own blood supply. During every step of this cycle the
tumor cells must also be capable of avoiding surveillance of the immune system
(64). Increasing evidence shows the stress response can affect many of the
processes in this cascade.

F.

Stress and angiogenesis
When a tumor begins to grow it must establish a vascular source to

provide oxygen and nutrients to the cells. Nutrients and oxygen can only diffuse a
matter of millimeters through tissue, and as such, formation of an adequate blood
supply is a critical early step in tumor growth. This process has been termed
angiogenesis

and

it

has

been

extensively

studied

in

human

cancers.
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Figure 3. Steps of tumor metastasis

(Figure used with permission from (157))
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Several factors may be responsible for promoting growth of blood vessels. There is
a great deal of literature describing the effects of stress on two potent angiogenic
factors, Vascular Endothelial Growth Factor (VEGF) and Interleukin‐6 (IL‐6).

Norepinephrine has been shown to increase production of VEGF
through activation of β‐AR/cAMP/PKA signaling (65), which can be mimicked by
isoproterenol (a β‐agonist) and blocked with β‐blockers (66). In animal models
norepinephrine increased CD31 positive staining, representing an increase in
vessel density and therefore angiogenesis (66). In patients, high social support was
associated with lower levels of VEGF (67).

IL‐6 is a pro‐inflammatory cytokine. Although its primary function is in
immunity, IL‐6 also plays a role in promoting angiogenesis. Under chronic stress
conditions, IL‐6 expression is increased in tumor cells through adrenergic
activation of Src signaling (68). Clinical evidence has shown that patients with poor
social support have higher levels of IL‐6 when compared to patients with good
social support (69) and these high levels are associated with poorer outcome in
patients (70).

G.

Adrenergic impact on migration and invasion of tumor cells
Tumor cells must gain the ability to migrate and invade to become

metastatic. Chronic stress has been shown to promote tumor cell migration in
breast and ovarian cancer cells through activation of β‐adrenergic receptors
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(66,71). Chronic stress also promotes tumor cell invasion through activation of
several promalignant pathways.

This invasion is primarily mediated through

activation of STAT3 signaling, which promotes invasion through increasing
expression of MMP‐2 and ‐9, both of which play a critical role in degrading the
basement membrane and allowing tumor cells to invade the vasculature and
thereby travel to metastatic sites (66,72‐73).

8.

Clinical impact of chronic stress
Several studies have now been done to investigate the possible patient

benefit of psychological interventions.

However, there is a great deal of

controversy over the studies that have been done with psychological/behavioral
interventions. For instance, many studies have looked only at so‐called “soft”
factors, such as quality of life and feelings of well‐being, as opposed to “hard”
factors, such as survival and cortisol levels, which a concrete value can be placed
upon.

Perhaps the most convincing of these studies was done at Ohio State

University. The group performing these studies found that placing patients in small
support groups resulted in decreased anxiety, improved social support, improved
immune response, and overall improved health. Follow‐up of 11 years on these
patients also revealed that patients who participated in the groups had reduced
chance of both recurrence and death (74‐76). Other studies have found that
psychological interventions reduce cortisol levels, improve immune response
(through measures of lymphocyte proliferation), and provide patients with an
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overall improved feeling of well‐being (77‐80). These studies suggest that
behavioral therapies may be a viable option for improving patient quality of life as
well as outcome, and merit further investigation.

Most of the preclinical studies of chronic stress effects on cancer have shown
these effects to be mediated primarily through the β‐family of adrenergic receptors.
As such, β‐blockers have been of interest for clinical use. To this point, most of the
studies have been either retrospective or have contained confounding factors. For
example, a retrospective study looked at the risk of developing prostate cancer in
patients taking β‐blockers, and found that these patients had significantly lower
risk (81). Another retrospective study looked at overall risk of cancer in patients
taking β‐blockers for cardiovascular disease, and found that these patients also had
reduced overall risk of developing cancer (82). Further observational studies have
demonstrated improved relapse‐free survival, secondary tumor formation, and
overall mortality in breast cancer (83‐84) as well as improved outcome in
melanoma (85‐86). No clinical trials have yet been performed to determine the
efficacy of these drugs in treating a patient’s cancer, however.

9.

Neurogenesis

A.

Embryonic neurogenesis
Development of peripheral neurons during embryogenesis is a fairly

well‐understood process.

Neurons originate in the neural crest from
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sympathoadrenal progenitor cells (87). These cells quickly begin migrating
ventrally and begin differentiating into catecholaminergic neurons. There is then a
period of cell death that results, as neurons are initially produced in excessive
numbers.

This period is controlled by neurotrophic factors, primarily Nerve

Growth Factor (NGF) and its family members, Neurotrophin‐3 (NT‐3) and Brain
derived neurotrophic factor (BDNF) (88‐89). NGF and NT3 signaling through
Tyrosine receptor kinase A (TrkA) maintain survival and direction in developing
neurons (90‐91). Conversely, signaling through the p75NTR receptor can lead to
apoptosis of neurons (92) in the absence of Trk receptor activation (93) or when
co‐activation of Trk and p75 receptors shifts in favor of p75. Once activated by
neurotrophins, the internal domain of p75 activates ceramide production leading to
cell death (93‐94). Most neuronal circuits track along blood vessels. Some studies
suggest that this may be a result of the high amounts of NT‐3 and moderate levels
of NGF secreted by vessels (95‐97), which may provide growth advantages and
direction as these circuits are developing.

B. Adult Neurogenesis and nerve growth
In human adults, neurogenesis has previously been thought to occur in only two
specific brain regions: the subventricular zone of the forebrain (98) and the dentate
gyrus region of the hippocampus (99) (Figure 4).

More recent studies are

beginning to demonstrate that neurogenesis can also take place in other regions of
the brain, suggesting that this process may be more widespread than previously
thought (100‐102). In adult CNS neurogenesis, maturing neurons are able to
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integrate into existing neuronal circuits (99). These maturing neurons migrate
along existing pathways (the rostral migratory stream or the mossy fiber pathway)
as they begin to integrate into signaling circuitry by extension of dendritic
extensions. This formation of new neurons within the CNS appears to play many
major roles in memory formation, learning, and normal emotional function. To my
knowledge, the only study previously describing adult neurogenesis outside of the
CNS showed that the carotid body contains glia‐like stem cells capable of forming
new glomus cells following hypoxia (103).

Much of what is known about adult peripheral neural growth and repair has
come from studies of wound healing. The first studies demonstrating that nerves
are capable of regenerating following damage appeared in the mid‐19th century.
Since then, many of the mechanisms and factors involved in this process have been
elucidated.

Many of the mechanisms are similar to those involved in neural

development during embryogenesis, with cells of the extracellular matrix
producing growth factors and guidance factors that first break down damaged
axons, and then induce axonogenesis for replacement (104). Most of these
processes appear to be mediated primarily through release of NGF and GDNF
family members as well as guidance provided by Schwann cells.
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Figure 4. Adult neurogenesis in the hippocampus

(Figure courtesy of Richard Smart, University of Arizona)
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C. Doublecortin
During neuronal maturation, precursors express several different markers,
some of which fade as the neurons mature, others of which increase throughout
maturation. One of these markers is doublecortin (DCX) protein. Found in all
neural progenitor cells and neuroblasts, doublecortin is frequently used as a
marker of adult neurogenesis.

As neurons mature and differentiate, DCX

expression decreases rapidly, as expression of mature neuronal markers increase.
Expression is usually completely absent after about 14 days (Figure 4). Brown et
al. first demonstrated use of DCX as a marker for adult neurogenesis due to its
transient expression (105). The high expression levels in new neurons, and quick
fading as more mature neuronal markers increase, makes this an ideal marker for
newborn neurons (105)

D. Brain Derived Neurotrophic Factor
Brain Derived Neurotrophic Factor (BDNF) plays a significant role in adult
neurogenesis as well as embryonic development of neural circuits. In the adult
brain, high expression of BDNF supports neurogenesis and neuroplasticity. It plays
critical roles in learning and memory, as BDNF deficient animals demonstrate
severe impairment of these functions (106). Overexpression of BDNF causes both
anxiogenic and anti‐depressant behavior (107). Interestingly, BDNF expression is
significantly downregulated under chronic stress conditions in neurogenic brain
regions (108‐109).
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E. Tropomyosinrelated Kinase B (Figure 5)
TrkB (Tropomyosin‐related kinase B) is the membrane‐bound receptor for
BDNF. This member of the Trk family of receptors is critical for BDNF effects on
neuronal growth and survival. During development, BDNF signaling through TrkB
activates MAPK/ERK, PLCγ, and PI3K pathways (100). Activation of PLCγ promotes
neurite outgrowth and both initiation and maintenance of long‐term potentiation in
target cells (110). Trk signaling through MAPK is essential for differentiation of
neuronal precursors (111). Neuronal survival is mediated through activated PI3K
signaling (112). Activation of TrkB signaling in neurons is critical not only for
development and survival at the neuron/cellular level, but also at the organismal
level, as TrkB(‐/‐) knockout is neonatally lethal, with animals dying by 3 weeks of
age due to neuronal death (113). Interestingly, TrkB expression is limited almost
exclusively to nervous tissue, but its expression has been found in ovarian cancer
(114).

10. Neurogenesis and chronic stress

A.

Association of neurogenesis with disease
Several diseases are thought to have roots in neurogenesis. Major depression,

for instance, is thought to arise from defects in neurogenesis (115‐117). Many
studies demonstrate that neurogenesis is inhibited during periods of chronic stress,
and many antidepressant drugs work by promoting neurogenesis (118‐120).
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Figure 5. BDNF/TrkB signaling in neurons

(Figure used with permission from 160)
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Interestingly, several studies have implicated BDNF expression as an important
factor in stress‐induced impairment of neurogenesis in the CNS. Under conditions
of chronic stress, BDNF expression is downregulated in neurogenic brain regions
(108‐109) by histone methylation (121) and corticosterones (122). In contrast,
very recent studies have demonstrated that chronic immobilization (restraint)
stress induces dendritic growth in the amygdala (123). Perhaps most interesting
was a study by Lakshminarasimhan and Chattarji that demonstrated that chronic
restraint stress not only caused dendritic atrophy in the hippocampus and
dendritic growth in the amygdala, but that this also correlated with significant
decreases in BDNF in the hippocampus and increases in the amygdala (124_. These
exciting data demonstrates that stress may play contrasting roles on neuron
growth through modulations in BDNF.

B. Nervous system impact on tumor progression
The connection linking the nervous system and tumor growth has been
relatively little studied. While many groups have demonstrated the presence of
nerves in tumors, hypotheses on their function and origin have, to this point, been
weak and highly correlative.

Work done by several different groups has

demonstrated that various tumor types secrete neurotrophic factors, and that
media conditioned by these cells is capable of inducing neurite outgrowth (125).
However, no direct mechanism has been demonstrated. Additionally, many studies
have demonstrated that neurotransmitters are capable of influencing tumor
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progression in both stress and non‐stress conditions. A limited number of studies
exist showing innervation of tumors (126‐128). Some recent data have suggested
that tumors are capable of recruiting nerves into the tumor (129). These studies
also demonstrate that there is a correlation between positive staining for nerve
markers and poorer outcome in cancer patients (129‐130). However, these studies
are very limited in scope and inconclusive about the role the nerves are playing and
how the tumors are recruiting them. Also, to date, no study has revealed the
mechanism by which nerves are recruited into tumor tissue.

11.

Study Impact

To date, no study has yet provided a mechanism for why tumoral catecholamine
levels are higher than systemic levels following chronic stress. Nor has any study
yet provided a mechanistic understanding of how nerves are recruited into tumors,
and what role they play there. The work presented in this thesis seeks to fill these
gaps by demonstrating that catecholamines are delivered by neurons directly into
tumor tissue under chronic stress conditions, and that chronic stress contributes to
neuronal recruitment through increasing expression of brain derived neurotrophic
factor in ovarian tumor cells.
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Methods

31

1. Reagents
Table 1.
Reagent
norepinephrine
epinephrine
isoproterenol
dibutyryl cAMP
8cpt‐2Me‐cAMP
cortisol
dexamethasone
forskolin
tanshinone IIA
KT5720
BRL37344
SP600125
prazosine
yohimbine
atenolol
butoxamine
propranolol
U0126
U73122
LY294002
SB203580
Brefeldin A
GGTI‐298
API‐2
hexamethonium Bromide
Recombinant NGF‐β

Provider
Sigma
Sigma
Sigma
Sigma
Tocris
Sigma
Sigma
Sigma
Sigma
Calbiochem
Sigma
Tocris
Sigma
Sigma
Tocris
Sigma
Tocris
Sigma
Sigma
Sigma
Tocris
Tocris
Sigma
Tocris
Sigma
Sigma

Working
Concentration
10 μM
10 μM
10 μM
100 μM
100 μM
10 μM
10 μM
10 μM
100 μM
1 μM
10 μM
25 μM
10 μM
10 μM
10 μM
10 μM
10 μM
10 μM
10 μM
1 μM
5 μM
100 μM
1 μM
10 μM
1 mg/kg/day
100 ng/mL

Methods Table 1. Reagents Used, provider, and working concentration.
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Table 2.
Antibody
Neurofilament (anti mouse)
Neurofilament (anti human)
BDNF
doublecortin
tyrosine hydroxylase
CD31
GFP
RFP
anti mouse HRP IgG1
anti mouse HRP IgG
anti rabbit secondary HRP
anti‐Rabbit Alexa 488
anti‐Rabbit Alexa 594
anti‐mouse Alexa 488
anti‐mouse Alexa 594
AMCA‐conjugated anti‐Rabbit
Hoechst

Provider
millipore
abcan
Abcam
abcam
millipore
PharMingen
abcam
abcam
Jackson Immunoresearch
Jackson Immunoresearch
Jackson Immunoresearch
jackson Immunoresearch
Invitrogen
Invitrogen
Invitrogen
Jackson Immunoresearch
invitrogen

Catalog Number
MAB1615
ab9035
ab72438
ab18723
mab318
ab13970
ab62341

code 111‐156‐047

Methods Table 2. Antibodies used, provider, and catalog number (where
available).

Lipfectamine 2000 transfection reagent was purchased from Invitrogen (Carlsbad,
CA). Unless otherwise noted, all media for tissue culture were obtained from
Invitrogen.

2. Cell lines
The source and derivation of HeyA8, SKOV3, and A2780 ovarian cancer cells
has previously been reported (2).

Cells were grown in RPMI medium

supplemented with 15% fetal bovine serum and 0.1% gentamicin sulfate. PC12
cells were a kind gift from Dr. Yixin Yao and its derivation and source has been
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described previously (131).

These cells were maintained in RPMI‐1640

supplemented with 10% horse serum and 5% fetal bovine serum. Colon cancer cell
lines were a kind gift from Dr. Lee Ellis and were maintained in MEM supplemented
with NAA (Mediatech), sodium pyruvate (Gibco), Glutamine (Gibco), and 10% FBS.
Their source and derivation have previously been described (132). Cells were
screened for mycoplasma, and all experiments were carried out while cells were
~70% confluent unless otherwise noted.

3. siRNA
SiRNA was used for gene expression knockdown both in vitro and in vivo. All
siRNAs were obtained from Sigma‐Aldrich (St. Louis, MO). Cells were transfected
according to manufacturer’s protocol. Briefly, for in vitro transfection cells were
plated at 15‐20% confluency. 8 μg (10 cm) or 2 μg (6‐well) of siRNA was diluted in
100 μL serum‐free media and allowed to incubate for 5 minutes. 30 μL (10 cm) or
5 μL (6‐well) of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was also diluted in
100 μL serum‐free media and allowed to incubate 5 minutes. Following incubation
the diluted siRNA and transfection reagent were combined and allowed to incubate
for 25 minutes before being added to cells. Total volume was then brought up to 15
mL (10 cm) or 2 mL (6‐well) using serum‐free media. The reactions were allowed
to continue for 5 hours, at which point 15% fetal bovine serum was added to halt
transfection. Knockdown efficiency was tested by qPCR at 24, 48, and 72 hours. For
all siRNAs tested 48 hours was sufficient, therefore all experiments were carried
out at 48 hours post‐transfection.
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For in vivo studies, siRNAs were incorporated into 1,2‐dioleoyl‐sn‐glycero‐3‐
phosphatidylcholine (DOPC), a neutral liposome delivery molecule extensively used
by our lab and previously described by (133). Incorporations were done in the
laboratory of Dr. Gabriel Lopez‐Berestein as follows: DOPC and siRNA were mixed
in the presence of excess tertiary butanol at a ratio of 1:10 siRNA:DOPC. Tween 20
was added to the mixture in a ratio of 1:19 Tween 20:siRNA/DOPC. The mixture
was vortexed, frozen in an acetone/dry ice bath, and lyophilized. Prior to in vivo
administration, the lyophilized mixture was hydrated with 0.9% saline to 20 µg/mL
concentration. Animals were treated at a 5 µg/mouse/treatment dose, therefore
100 µL of the hydrated mixture was injected intra‐peritoneally into each mouse.

4. Neurite extension assay (FIGURE 6)
Neurite extension assays were used to assess neurite outgrowth in neuron‐
like PC12 cells. 24‐well inserts with 1 µM pore size were purchased from Millipore
and uniformly coated with type 1 rat‐tail collagen. PC12 cells were plated at 30%
confluency and maintained for 72 hours prior to plating for the assay in DMEM
containing 1% fetal bovine serum and 1 ng/mL recombinant NGF (nerve growth
factor) to induce differentiation. After 72 hours of treatment the cells were lifted
and plated in the coated inserts. Culture media containing rNGF was placed in the
top of the inserts and in the bottom of control wells. Media conditioned by ovarian
cancer cell lines was placed in the bottom of wells (see section 5 below). Plates
were placed in the incubator for 48 hours to allow neurite extension. After 48
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Figure 6. Neurite Assay Protocol
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hours the wells were removed. Media was removed using a vacuum manifold. Cells
were fixed in ice‐cold methanol for 20 minutes then washed in PBS. They were
then stained in neurite stain solution (Millipore) and again rinsed in PBS. Once
thoroughly rinsed, cell bodies remaining on the upper surface of the membranes
were removed using cotton swabs and PBS. The membranes were then allowed to
dry overnight before being removed from inserts, placed on a microscope slide and
coverslipped.

Five 40x objective fields were counted per membrane, and all

treatments were done in duplicate, for a total of 10 fields per treatment group.
Each branch was counted as a separate neurite extension, with no bias given to
length or size of the extension.

5. Conditioned media
For experiments requiring media conditioned by ovarian cancer cell lines,
serum‐free media was used and all media remained on cells for 24 hours prior to
being collected. For cells that were treated with norepinephrine, the cells were
serum starved overnight, and new media was added at the time of treatment. The
conditioned media was then collected 24 hours post‐treatment.

For media

conditioned by cells treated with siRNA, the cells were transfected at time 0, media
replaced with serum‐free media at 48 hours post‐transfection, and collected at 72
hours post‐transfection. For cells treated with both siRNA and norepinephrine
(NE), cells were serum‐starved from 36‐48 hours post‐transfection, new media
containing NE given at 48 hours, and collected at 72 hours post‐transfection.
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Conditioned media from each treatment group was used for subsequent neurite
extension assays.

6. Migration and Invasion assays
For all migration and invasion assays, 24‐well inserts containing a
polycarbonate membrane with 8 µM pore size was used. For migration assays the
inserts were uniformly coated with 0.1% gelatin at room temperature for 2 hours.
After allowing the matrix to dry, a single cell suspension of 5 x 104 cells was plated
per well with media containing 1% fetal bovine serum in the upper well and media
containing 5% fetal bovine serum in the lower chamber to encourage migration.
After an 8 hour incubation in a humidified incubator at 37C with 5% CO2, the
membranes were fixed and cells stained using a kit by Fisher Scientific. Cells
remaining on the upper surface of the membrane were removed following fixation.
Once dry the membranes were placed on microscope slides and coverslipped.
Counting was performed using light microscopy on a total of 5 high power fields
per insert.

When required, cells were treated with siRNA 48 hours prior to

migration to ensure complete gene knockdown.

For invasion assays, inserts were coated with a defined basement membrane
matrix consisting of human laminin, type IV collagen, and gelatin. This coating is in
place to mimic the basement membrane that tumor cells must degrade in order to
invade into the surrounding tissues. Cells were plated as described for migration
assays and incubated for 24 hours to allow time for matrix breakdown.
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7. In vivo Models
All experiments using human cell lines were done in 8‐ to 12‐ week old
female athymic nude mice received from Taconic Farms (Hudson, NY).
Experiments using mouse cell lines were performed in C57/B6 lineage mice. All
experiments were approved by the M. D. Anderson Institutional Animal Care and
Use Committee (IACUC)

8. Chronic stress model
In order to mimic chronic adrenergic activation caused by chronic stress in
humans we utilize a daily restraint stress system developed by our lab (2). In our
system, boxes have been created that allow 10 mice to be placed in individual slots,
each containing a moveable wall that allows us to restrain the animals in a
movement‐restricting space for the desired length of time.

Our group has

previously tested various lengths of time for daily restraint and found that 2 hours
daily produces significant increases in tumor growth, while longer lengths of time
did not seem to add any additional effect (2). I therefore utilized 2 hours of
restraint stress daily for 1 week prior to tumor cell injection, and continuing for 2
weeks post injection.

Unless otherwise noted, animals are necropsied at

approximately 28 days following tumor cell inoculation.
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Figure 7. Restraint stress boxes. Animals are placed in individual compartments
and moveable walls are put in place to confine the animals to a small, movement‐
restricting space.
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9. Tumor cell inoculation
To prepare tumor cells for inoculation, cells were plated and allowed to grow until
60‐70% confluent to ensure they were still in the exponential growth phase. Cells
were then washed and lifted using 0.25% trypsin/EDTA. After lifting, trypsin was
inactivated using media supplemented with FBS. Cells were spun down for 5
minutes at 1300 rpm, washed and resuspended in Ca2+/Mg2+‐free Hanks Buffered
Saline Solution (HBSS). Cells viability was tested using trypan blue and then
counted. The volume containing the desired number of cells was then removed and
spun down again, and re‐suspended in HBSS to the desired concentration.
Injections were done in a volume of 200 μL per mouse intraperitoneally. Cell
numbers used for injection were as follows:

Cell line

Cell number injected

SKOV3‐ip1

1 x 106

HeyA8‐ip1

2.5 x 105

RKO‐ip1

3 x 106

ID8‐VEGF

1 x 106

10. In Vivo siRNA treatments
SiRNA treatments began on day 5 following tumor cell inoculation. This
time lapse was allowed to ensure that knockdown of the target gene would not
affect tumor cell adhesion within the peritoneal cavity. Previous in vitro and in vivo
studies n our laboratory have shown effective knockdown for up to 72 hours
following a single siRNA treatment (134).

We therefore treated our animals
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biweekly with 5 μg siRNA per mouse. As described above, siRNA was incorporated
into the DOPC liposome and delivered in a 0.9% saline solution intraperitoneally.
Expression knockdown was confirmed using quantitative PCR.

Our laboratory has shown that Chitosan nanoparticles have more effective
delivery to peripheral nerve endings.

Therefore, in order to achieve optimal

delivery to the neurons, the mTrkB siRNA was incorporated in Chitosan
nanoparticles rather than DOPC. The particles were injected intravenously through
the tail vein twice weekly.

11. Surgical models
Animals receiving hexamethonium bromide received surgical implantation
of Alzet mini‐osmotic pumps. These pumps ensure continual delivery of a drug and
are approved for up to 42 days of continual delivery. Animals were anesthetized
using Isoflurane inhalant anesthesia. A 1 cm incision was made dorsally between
the shoulder blades through only the skin, not penetrating the muscle layers. Blunt
ended scissors were used to separate connective tissue beneath the skin. Pumps
were inserted into the gap made and the incisions were closed using surgical
wound clips, which were removed 7 days post‐surgery. Osmotic pumps were dry
when loaded with drug. This allowed a delay of up to 72 hours from the initial time
of implantation before drug was secreted. Tumor cells were injected at the time of
surgery, and this time was to allow tumor cells time for implantation.
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Figure 8. Schema for in vivo experiments utilizing BDNF siRNA.
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Adrenalectomized animals were received from Taconic Farms. Animals
were shipped 3 days following surgery and allowed 10 additional days for recovery
prior to onset of stress. Sham surgeries were performed on age‐matched C57/B6
mice provided by M.D. Anderson department of Experimental Radiation Oncology.
Animals were anesthetized using a ketamine‐based anesthesia (100 mg/kg
Ketamine, 2.5 mg/kg Xylazine, 2.5 mg/kg Acepromazine), and a dorsal incision
measuring approximately 1 cm was made on each mouse through the skin. A flank
incision was then made through the muscle layer on the right side of each animal.
Sterile cotton swabs moistened with sterile PBS were inserted into the incision and
manipulated within the animal to mimic adrenalectomy surgery. Muscle incisions
were sutured using Lycril. External skin incisions were closed using wound clips.
Post‐surgery all animals were maintained on 0.89% saline water.

For intraovarian injections animals were anesthetized with ketamine‐based
anesthesia. Flank incisions were made on the right side of the animal and the ovary
located with the aid of PBS‐moistened cotton swabs. 1 x 106 SKOV3‐ip1 ovarian
cancer cells were injected into the ovary as a single cell suspension using a 30‐
gauge hypodermic needle. Tumors were allowed 5 weeks to grow and metastasize
before necropsy.

12. Patient Sample Immunohistochemistry
Human ovarian tumor clinical specimens were received from the M.D.
Anderson gynecology oncology tumor bank following approval by the Institutional
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Review Board.

Formalin‐fixed, paraffin‐embedded tumors (both primary and

metastatic sites) from 67 patients were stained for Neurofilament, Tyrosine
hydroxylase, and BDNF. Slides were placed in an oven overnight at 65°C and
passed through xylene to remove the paraffin and were rehydrated in PBS. Antigen
retrieval was performed in a 10 mM citrate solution in the microwave at 98°C for
10 minutes and allowed to cool to room temperature over approximately 1.5‐2
hours.

Endogenous peroxidase activity was blocked by incubation in a 3%

hydrogen peroxide solution in methanol for 12 minutes. Tissues were incubated at
room temperature in a solution of 4% cold‐water fish gelatin in PBS for protein
blocking. Tissues were incubated with primary antibodies diluted in protein block
temperature in a humidified chamber overnight at 4°C. Secondary antibodies were
diluted in protein block and incubated on tissues for 1 hour at room temperature in
a humidified chamber overnight at 4°C. DAB was applied and development was
monitored under a light microscope to prevent over‐exposure (approximately 4‐6
minutes). Gill’s hematoxylin was used for 10 seconds on samples for nuclear
counterstain. Samples were dried and coverslipped. Light microscopy was used for
visualization of nerves using the 40x objective. The 20x objective was used for
BDNF visualization.

Samples were scored according to both percentage and

intensity of staining.
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13. Statistical Analysis
Continuous variables were compared using either a student’s t‐test or
analysis of variance (ANOVA). We used the non‐parametric Mann‐Whitney test to
compare differences. Two‐way ANOVA was used to determine sample size. We
determined a sample size of 10 animals per group would provide an effect size
(ration of fixed effect and residual standard deviation) of 1.3 with 80% power at a
significance level of p=0.05, which we considered to be significant.

46

Results
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1. Nerve density in human ovarian cancer
My first goal was to determine whether nerves are present in human
ovarian cancers. I therefore examined 160 high‐grade epithelial ovarian cancers
from both primary and metastatic sites from 67 patients. It is postulated that these
tumors develop from the surface epithelium of the ovary, and, while the cortex of
the ovary has significant nervous supply, this layer does not. Additionally, ovarian
cancer tends to metastasize within the peritoneal cavity, frequently developing in
the omentum and mesentery, neither of which is highly innervated. My analysis
revealed that neurofilament, a marker for mature and developing neurons, was
present in > 60 percent of samples analyzed, indicating that ovarian cancers are
innervated (Figure 9A). Nerves were found in both primary tumors from the ovary
and metastatic tumors found in the omentum, peritoneum, and a variety of other
sites. There was no evidence that innervation of tumors was site specific.

Samples were divided into those with high versus low nerve density and
survival analysis performed. This analysis showed that those patients whose
tumors had high nerve density had an average survival time of 39 months, versus
65 months in patients with low nerve density (Figure 9B).

This statistically

different result suggests that tumor neo‐innervation may be an important marker
for patient outcome.
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A.

Representative photos of neurofilament in human ovarian cancer
specimens

B.

p< 0.01

Figure 9. Nerve Density in human ovarian cancers. A. Representative
sections of neurofilament staining in human ovarian tumor samples. B.
Overall patient survival in patients with high versus low nerve density.
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2. Norepinephrine stimulates neurotrophin expression in ovarian
cancer cells
Recent work in our lab and others has demonstrated that chronic stress can
significantly promote tumor progression through high levels of catecholamines
present within the tumor. Catecholamines are primarily produced by sympathetic
nerve endings. I therefore hypothesized that neurons present within the tumor
may be responsible for the high levels of catecholamines found in tumor tissue.
This led me to question what signals promoted nerve growth into the tumor.

Neurotrophic factors are responsible for promoting survival, growth, and
proliferation of neurons, and are ubiquitously expressed throughout the body. I
therefore chose to screen a panel of human ovarian cancer cell lines to determine
whether tumor cells also express these factors.

Using quantitative reverse

transcription PCR I found that 7 different ovarian cancer cell lines expressed
members of the nerve growth factor family of neurotrophins, and that their
expression was increased over non‐transformed ovarian surface epithelium cells
(Figure 10A). Previous work from our lab has demonstrated that chronic restraint
stress results in increased tumor growth and progression through activation of β
adrenergic receptors (ADRB) and glucocorticoid receptors on tumor cells.

Adrenergic stimulation has been shown to activate signaling pathways
known to regulate neurotrophic factors. I therefore hypothesized that stress
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A.

B.
Gene

HeyA8
NE tx

SKOV3
NE tx

Artemin 1.39

1.78

BDNF

4.19

2.63

NGF

0.43

0.27

C.

Figure 10. Neurotrophin expression in ovarian cancer cells. A.
Expression of neurotrophins in ovarian cancer cells. B. Neurotrophic
factors significantly increased in both HeyA8 and SKOV3 cells following
norepinephrine stimulation. C. Timecourse of BDNF expression in SKOV3
cells following stimulation with norepinephrine, epinephrine, or cortisol.
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hormones would increase expression of neurotrophic factors. I first treated several
ovarian cancer cell lines with norepinephrine (NE), epinephrine (Epi),
isoproterenol (a nonspecific ADRB agonist), and cortisol. Quantitative PCR analysis
showed increased expression of Nerve Growth Factor (NGF) and Glial cell‐derived
neurotrophic factor (GDNF) family members such as BDNF and artemin following
stimulation with NE, isoproterenol, and, to some extent, epinephrine. Cortisol had
little to no effect on the neurotrophic genes examined, suggesting that these
increases are in fact mediated through the ADRB family of receptors rather than
glucocorticoid

receptors.

NE

treatment

caused

increased

expression

in

neurotrophins within 30 minutes, with peak increases seen between 3 and 6 hours
post‐treatment (Figure 10C). To expand my analysis to a broader spectrum of
neurotrophins, I used a quantitative PCR array to examine members of the NGF and
GDNF families as well as other known neurotrophic factors and related receptors.
After exposing cells to NE for 6 hours, my analysis showed upregulation of two
genes of particular interest, BDNF and artemin (Fig 10B).

3. Ovarian cancer cells promote neurite extension
To determine whether ovarian cancer cells are capable of promoting neurite
extension, I utilized a neurite extension assay (Figure 6). Due to the difficulty in
isolating and culturing neurons of the peripheral nervous system, I used the PC12
pheochromocytoma cell line. When stimulated with Nerve growth factor (NGF),
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these cells differentiate and closely resemble neurons of the peripheral nervous
system (132). Media conditioned by ovarian cancer cells was capable of promoting
neurite extension (Figure 11A), and addition of NE to ovarian cancer cells
potentiated this effect (Figure 11B).

Taking into consideration the increase in BDNF and artemin seen following
NE stimulation of ovarian cancer cells, I next chose to silence expression of these
neurotrophic factors using siRNA to determine whether they might be playing a
role in promoting neurite extension. Exposure to media conditioned by BDNF
siRNA treated cells abrogated NE‐induced increases in neurite extension (p value =
0.15 of treatment vs. no treatment) (Figure 11E) compared to exposure to media
conditioned by control siRNA treated cells (Figure 11C). Silencing artemin had no
significant effect (p value < 0.01 in treatment vs. no treatment) (Figure 11D). These
results suggested that BDNF might be responsible for promoting nerve growth
following adrenergic activation. Based on these results I next decided to test the
role of BDNF in recruitment of nerves into tumors in an orthotopic mouse model of
ovarian cancer.
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A.

B.

C.

D.

E.

F.

G.
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Figure 11. Neurite Extension Assays. A. Representative photos of
neurite extension assays with tumor cell conditioned media versus
BSA control media chemoattractant. B. Average neurite extensions per
hpf of PC12 cells in response to media conditioned by SKOV3 ovarian
cancer cells stimulated with isoproterenol, norepinephrine, or cortisol.
C. Average neurite extensions per hpf of PC12 cells in response to
media conditioned by SKOV3 ovarian cancer cells treated with
control/non‐targeting siRNA and subsequently stimulated with
isoproterenol or norepinephrine. D. Average neurite extensions per
hpf of PC12 cells in response to media conditioned by SKOV3 ovarian
cancer cells treated with Artemin siRNA and subsequently stimulated
with isoproterenol or norepinephrine. E. Average neurite extensions
per hpf of PC12 cells in response to media conditioned by SKOV3
ovarian cancer cells treated with BDNF siRNA and subsequently
stimulated with isoproterenol or norepinephrine. F. Knockdown
efficacy of artemin siRNA. G. Knockdown efficacy of BDNF siRNA.
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4. Chronic stress promotes neoinnervation of tumors in a BDNF
dependent manner

A. Tumors taken from chronically stressed mice have higher nerve density
than tumors taken from nonstressed mice
To study the biological consequences of the increased neurite extension seen in
vitro, I used a chronic restraint stress system to induce adrenergic activation in
vivo. Daily restraint stress has been shown to activate the SNS and stimulate
production of catecholamines, resulting in increased tumor growth.

Semi‐

quantitative analysis of immunohistochemical staining of neurofilament in tumor
samples taken from animals that underwent daily restraint stress exhibit a 3‐fold
increase in nerve density when compared to tumors obtained from non‐stressed
control animals (Figure 12).

B. Chronic stress impact on nerve density in normal tissue
The above results then led me to consider whether chronic stress increases
native nerve density of normal tissues in non tumor‐bearing animals. To test this I
removed liver, spleen, omentum, ovary, and peritoneum from both chronically
stressed and non‐stressed non tumor‐bearing mice. Analysis of nerve density in
these tissues revealed no significant changes in nerve density between stressed and
non‐stressed animals (Figure 13B), suggesting stress‐induced nerve growth may be
tumor‐specific.
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A.

B.

Figure 12. Nerve density in tumors of chronically stressed mice A.
Representative photos of neurofilament immunohistochemical staining in
SKOV3 tumors taken from stressed or non‐stressed animals. B. Average
nerve density per hpf in SKOV3 tumors taken from stressed or non‐
stressed animals.
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C. The role of nerve density in metastasis
Evaluation of patient samples suggested that tumor innervation is not site
specific. To confirm this observation, I utilized an intraovarian model of ovarian
cancer metastasis with or without chronic stress. In this model, tumor cells are
injected directly into the ovary and allowed to metastasize. Tumors were then
collected and analyzed for nerve density at the metastatic site. Nerves were seen in
tumors taken from spleen, ovary, peritoneum, omentum, and liver. As shown in
figure 13B, nerve density in these tissues varies greatly, suggesting that native
nerve density does not play a significant role in predilection of tumors to
metastasize to certain sites.

In the intraovarian model of ovarian cancer metastasis, tumors most
frequently metastasized to the peritoneum, surgical wound site (resulting from
injections), and the mesentery. Analysis of tumors taken from each of these sites
revealed that chronic stress increased nerve density in tumors from all three sites
(Figure 13A), suggesting that chronic stress increases in nerve density are not site
specific.

D. siRNA silencing of BDNF in tumor cells inhibits stressinduced neo
innervation of tumors
I next wished to investigate whether inhibition of BDNF expression in tumor
cells would affect neo‐innervation of tumors in vivo. To silence expression of BDNF
58

A.

B.

Figure 13. Nerve density of tumors taken from metastatic sites. A.
Nerve density from metastatic ovarian tumors from various sites. B. Nerve
density of various tissues from non tumor‐bearing animals
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I used siRNA incorporated into a neutral DOPC liposomal delivery system. Our lab
has done extensive testing of siRNA in in vivo models, and has found that use of this
liposome for high degree of delivery into tumor tissues (134). Additional testing
has demonstrated that we can achieve significant inhibition lasting over 72 hours
from one treatment (134). Animals were therefore treated biweekly to ensure
continuous knockdown of BDNF expression. Use of an orthotopic mouse model of
ovarian cancer allowed me to use a human‐BDNF‐specific (hBDNF) siRNA to inhibit
BDNF production in the tumor without affecting BDNF production in other tissues.
Tumors were collected from stressed and non‐stressed animals treated with either
scrambled, nontargeting control or hBDNF targeting siRNAs.

Tumors were

analyzed for BDNF expression using both qPCR and IHC. Additional IHC analysis
was also used to count nerve density. Analyses revealed that BDNF expression
increased over 9‐fold in tumors from stressed animals versus non‐stressed (Figure
14A and B), demonstrating that the increases in BDNF seen following NE
stimulation in vitro are significantly amplified in vivo. As anticipated, tumor weight
was doubled in stressed versus non‐stressed control siRNA treated animals. More
interestingly, this effect was entirely abrogated in animals treated with hBDNF
siRNA. While hBDNF inhibition had no significant effect in non‐stressed animals, it
entirely abolished stress‐induced increases in tumor growth in animals receiving
daily restraint stress (Figure 14C). Further analysis revealed that hBDNF inhibition
also abrogated stress‐induced increases in tumor neo‐innervation (Figure 14E).
While tumors from control siRNA treated chronically stressed mice had an average
of 6 nerves per high powered field,
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A.

B.

C.

D.

E.

Figure 14. BDNF siRNA in SKOV3 tumors. Relative BDNF expression by
A. IHC and B. qPCR in SKOV3 tumor samples C. Average total SKOV3 tumor
weight, D. tumor nodules, and E. Average nerve density per hpf in stressed
versus non stressed animals that underwent either adrenalectomy or
sham surgery.
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hBDNF siRNA treated stressed mice had no nerves present. Similar results were
also seen in tumors from the HeyA8 ovarian cancer cell line (Figure 15).

To demonstrate that stress‐induced tumor neo‐innervation is not an ovarian
cancer‐specific phenomenon, I repeated these experiments using the RKO human
colon cancer cell line. Upon NE stimulation in vitro, BDNF expression increases in
these cells. In vivo chronic stress increased tumor weight and nerve density in
these tumors by 2‐fold (Figure 16), and as in the ovarian cancer models, BDNF
inhibition using hBDNF‐targeted siRNA abrogated stress effects on both tumor
growth and nerve density. Taken together, these data suggest not only that chronic
stress promotes neo‐innervation of tumors, but also that tumor neo‐innervation is
critical for chronic stress‐induced effects on tumor growth, and that BDNF
production from the tumor is a crucial factor in this process.

5. BDNF expression correlates with nerve density and patient
outcome in human ovarian cancer patients
I next wished to determine whether there was a correlation between high
nerve density and BDNF expression in human ovarian cancers.

I therefore

measured BDNF levels semi‐quantitatively by IHC analysis in patient samples
previously stained for nerve density. Patients were divided into high and low BDNF
expression (Figure 17A). This analysis revealed a positive correlation between
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A.

B.

Figure 15. BDNF siRNA in HeyA8 tumors. A. Average total tumor weight
of HeyA8 tumors and B. average nerve density in stressed versus non
stressed animals treated with either control or BDNF siRNA.
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A.

B.

Figure 16. BDNF siRNA in RKO colon cancer. A. Average total tumor
weight and B. Average nerve density per hpf of RKO tumors taken from
stressed or non‐stressed animals treated with control or BDNF siRNA
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increased BDNF expression and increased nerve density. There was also a
significant correlation between high BDNF expression and poor outcome (p<0.001)
(Figure 17B). Patients with high levels of BDNF expression survived an average of
39 months, compared with 65 months in patients expressing low levels of BDNF.

6. Neural precursors are present in tumors
We next wondered about possible origins for the nerves noted in the
tumors. Increased nerve density may be a result of branching of existing neurons,
or occurs by formation of new neurons from precursor cells. Doublecortin is a
protein expressed exclusively in neuronal precursors and immature neurons. Its
expression decreases and ultimately disappears after the first 10‐14 days of a
neuron’s existence (Figure 4). It is therefore used as a marker for new neuron
formation. IHC analysis of tumors taken from chronically stressed mice revealed
the presence of doublecortin positive cells within the tumors (Figure 18). This
evidence demonstrates that signals activated by chronic stress, and most likely
coming from the tumor itself, are initiating new neuron formation through the
recruitment of neuronal precursors.

65

A.

B.

p< 0.01

Figure 17. BDNF expression in human ovarian cancer. A. BDNF
expression in human ovarian cancer samples. B. Overall survival of
ovarian cancer patients with high versus low BDNF expression.
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Figure 18. A. Doublecortin positive cells in SKOV3 ovarian tumors
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7. Inhibition of neoinnervation of tumors abrogates downstream
stress effects
Previous studies from our lab have shown that chronic stress activates
several processes critical for tumor growth and progression. For a malignancy to
progress it must gain an adequate blood supply to provide nutrients and growth
factors to the tumor cells. IL‐6 is a prominent factor in this process. Our previous
studies have shown a several fold increase in IL‐6 following chronic stress both in
animal models and clinically (2, 68). Additionally, in order to metastasize tumors
must be able to invade the surrounding basement membrane through the function
of matrix metalloproteinases (MMPs). Our studies have also shown two MMPs,
MMP‐2 and ‐9, are significantly increased following chronic stress. I therefore
wished to determine whether inhibition of tumor neo‐innervation affected other
markers of chronic stress in tumors. Quantitative‐PCR analysis demonstrated that
IL‐6 expression in tumors of chronically stressed mice was increased over 7‐fold
compared to non‐stressed controls, and this increase was entirely abrogated in
hBDNF siRNA treated animals (Figure 19A).

Additionally, MMP‐2 and ‐9

production increased 19‐ and 10‐fold respectively in tumors from chronically
stressed animals, but no significant increase was seen in tumors taken from hBDNF
siRNA treated animals (Figure 19B and C). These data suggest that by inhibiting
neo‐innervation of tumors, we are also inhibiting downstream effects of chronic
stress.
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A.

B.

C.

Figure 19. Downstream markers of chronic stress following BDNF
inhibition in vivo. Relative expression of A. MMP‐2, B. MMP‐9, C. IL‐6 in
SKOV3 tumors taken from stressed or non‐stressed mice treated with
either control or BDNF siRNA
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8. TrkB receptors on tumor cells play no significant role in stress
induced tumor growth
Members of the nerve growth factor (NGF) family bind to the Trk family of
tyrosine kinase receptors. These receptors are known to be overexpressed in
ovarian cancers. BDNF binds with high affinity to TrkB, and activation of TrkB by
BDNF in ovarian cancer cells has been shown to slightly increase tumor cell
migration, while inhibition of TrkB impaired migration and invasion (135). To
verify that effects seen on tumor growth are an indirect effect mediated through
decreased tumor neo‐innervation as opposed to a direct effect on the tumor cells
themselves, I treated nude mice bearing SKOV3 human ovarian cancer tumors with
human TrkB targeted siRNA. hTrkB inhibition had no significant effect on total
tumor weight in either stressed or non‐stressed animals (Figure 20C). Conversely,
inhibition of mTrkB was capable of entirely abrogating stress‐induced tumor
growth (Figure 21), suggesting that autocrine signaling of BDNF on TrkB receptors
found on the tumor cells themselves are not a significant mechanism used by
chronic stress to induce tumor growth., while paracrine signaling through other
cells expressing TrkB receptor, mainly nervous tissue, does play a significant role.
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A.

B.

C.

Figure 20. hTrkB siRNA in vivo. A. Relative mTrkB expression in ID‐8
mouse ovarian tumor cells treated with hTrkB siRNA. B. Knockdown
efficacy of hTrkB siRNA. C. Average total SKOV3 tumor weight from either
stressed or non‐stressed mice treated with either control or hTrkB siRNA.
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Figure 21. mTrkB siRNA in vivo. Average total SKOV3 tumor weight
from either stressed or non‐stressed mice treated with either control or
mTrkB siRNA.
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9. Inhibition of peripheral nervous system function blocks stress
mediated tumor growth and innervation
Hexamethonium Bromide is a ganglionic blocker that blocks nicotinic
receptors of postganglionic neurons. Interestingly, hexamethonium is only capable
of crossing the blood‐brain‐barrier at very high doses. Therefore, given at low
doses it can serve as a peripheral nervous system‐specific antagonist. As a result,
this drug has been used for many years to study peripheral nervous system
function. As shown in Figures 1 and 2, the central nervous system initiates the
stress response systems through the hypothalamic‐pituitary‐adrenal axis and
autonomic nervous system. In my studies, I sought to demonstrate that the effects
of chronic stress that we see on tumor growth are mediated through the peripheral
nervous system function rather than direct CNS control. I compared tumors taken
from stressed and non‐stressed animals that were given either vehicle (PBS) or 1
mg/kg/day hexamethonium bromide, a dose significant enough to inhibit PNS
function, without crossing into the CNS. Average tumor weight in chronically
stressed animals treated with hexamethonium was similar to the baseline tumor
weight found in non‐stressed vehicle treated animals, and significantly reduced
when compared to tumor taken from chronically stressed vehicle treated animals
(Figure 22A). Interestingly, I found that nerve density in these animals was also
decreased (Figure 22B). These results suggest that peripheral nervous system
function is a critical mediator of chronic stress effects on tumor growth, and
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A.

B.

Figure 22. Hexamethonium Bromide treatment in vivo. A. Average
total SKOV3 tumor weight and B. Average nerve density per hpf in
stressed versus non stressed animals treated with either PBS control or
hexamethonium Bromide.
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supports my hypothesis that neurons of the peripheral nervous system found in
tumors may be contributing to promoting these effects.

10.

Circulating catecholamines do not significantly affect tumor

progression in mouse syngeneic model of ovarian cancer
There are two main pathways downstream of the central nervous system
that become activated as our bodies cope with a stressor. One pathway is the
sympathetic nervous system, which signals through catecholamines released
primarily by sympathetic nerve endings. The other pathway is the hypothalamic‐
pituitary‐adrenal axis (Figure 1B).

This pathway results in secretion of

glucocorticoids and catecholamines from the adrenal glands to circulate
systemically in the blood stream.

Though this is not the primary method of

secretion for catecholamines, I wished to verify that the hormones seen within the
tumor tissue are in fact coming from sympathetic nerve endings, rather than being
deposited in the tumor through circulation from the adrenal gland. To test this
hypothesis I utilized an adrenalectomized mouse model. Due to low survival rates
in nude mice when performing adrenalectomy surgeries, I used adrenalectomized
C57/B6 mice. Our lab has previously used a line of ID8 mouse ovarian tumor cells
that express high levels of VEGF for syngeneic models of chronic stress in ovarian
cancer. Expression of neurotrophins and ability to induce neurite extension were
similar in this cell line to those seen with the SKOV3 human ovarian cancer cell line,
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so I chose to utilize this line for this model. Following either adrenalectomy
surgery or sham surgery, adrenalectomized mice were given 10 days to recover
prior to the initiation of daily stress. These animals were then treated according to
our previously established model of chronic stress in vivo (Figure 8). Total tumor
weight of tumors taken from chronically stress, adrenalectomized animals was very
similar to total tumor taken from chronically stress, sham surgery animals (Figure
23A). This result suggests that stress hormones being delivered into the tumor
from the adrenal gland play no significant role in promoting stress‐induced tumor
progression. Further analysis revealed that nerve density in tumors from both
groups was also similar (Figure 23B), suggesting that hormones from the adrenal
gland also do not play a role in initiating neo‐innervation of tumors.

11.

Norepinephrine stimulates BDNF production in ovarian

tumor cells through the ADRB3cAMPEpac signaling pathway
Previous data from our lab have revealed that stress effects on tumor
growth are mediated through the β2‐Adrenergic receptor (ADRB2) (2). All
members of the ADRB family are expressed in ovarian cancer cell lines. I therefore
sought to discover which receptor and downstream signaling pathways are
involved in adrenergic‐induced increases in BDNF expression. Using receptor‐
specific inhibitors I found that NE‐induced BDNF expression occurs through the β3‐
adrenergic receptor (ADRB3). Inhibition of α‐adrenergic receptors (Figure 24A) as
well as the β1‐ and β2‐ (Figure 24 B; atenolol, butoxamine, and propranolol)
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A.

B.

Figure 23. Tumor weight and nerve density in tumors of
adrenalectomized mice. A. Average total SKOV3 tumor weight and B.
Average nerve density per hpf in stressed versus non stressed animals
that underwent either adrenalectomy or sham surgery.
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adrenergic receptors had little or no impact on NE‐induced BDNF expression, while
inhibition of the β3 family member entirely abrogated NE‐induced BDNF expression
in ovarian cancer cells (Figure 24B, SR59230). Conversely, stimulating with the
ADRB3‐specific agonist BRL37344 increased BDNF expression (Figure 24C).
ADRB3 is a G‐protein coupled receptor that functions primarily through the
cAMP/PKA signaling pathway, though it can also signal through the Ras and PI3K
pathways. I verified cAMP involvement by using forskolin, a cAMP agonist, which I
found increased BDNF gene expression (Figure 25A). Activation or inhibition of
PKA signaling had no effect on NE‐induced BDNF expression (Figure 26F).

I

therefore chose to look into the less common Epac signaling pathway. Inhibition of
Epac using Brefeldin A markedly decreased NE‐induced increases in BDNF gene
expression (Figure 25B). Conversely, activation of Epac using 8cPT‐2Me‐cAMP, a
cAMP mimic that is specific to Epac family members, induced BDNF gene
expression (Figure 25B). Further inhibition of factors downstream of Epac pointed
to involvement of JNK activation (Figure 25C). Luciferase studies have confirmed
that NE induces BDNF expression through ADRB3, and this signaling is mediated
through Epac.

To further validate this pathway, I inhibited several other pathways known
to be downstream of ADRBs, cAMP, or Epac. Inhibition of PLC, Akt, and MEK had no
significant effect on NE‐induced BDNF expression (Figure 26A). Additionally,
inhibition of H‐ or K‐Ras using siRNA no significant effect on NE‐induced BDNF
expression. Nor did inhibition of PKB or Rap signaling. These studies, summarized
78

in Figure 27, demonstrate that norepinephrine activates ADRB3 which then signals
through cAMP to activate Epac and initiate downstream JNK signaling to promote
BDNF gene expression.
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A.

B.

C.

Figure 24. Norepinephrine signals through ADRB3 to increase BDNF
expression. A. Relative BDNF expression in norepinephrine stimulated
SKOV3 cells treated with Prazosin or Yohimbine. B. Relative BDNF
expression in norepinephrine stimulated SKOV3 cells treated with
atenolol, butoxamine, propranolol, or SR59230. C. Relative BDNF
expression in SKOV3 cells treated with BRL 37344.
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A.

B.

C.

D.

Figure 25. Norepinephrineinduced increases in BDNF expression
are mediated through cAMP, Epac, and JNK. A. Relative BDNF
expression in SKOV3 cells treated with norepinephrine or Forskolin. B.
Relative BDNF expression in norepinephrin stimulated SKOV3 cells
treated with Brefeldin A and non‐stimulated SKOV3 cells treated with
8cPT‐2Me‐cAMP. C. Relative BDNF expression in norepinephrine
stimulated SKOV3 cells treated with SP600125 or Tanshinone IIA. D.
Relative BDNF promoter activity in norepinephrine stimulated SKOV3
cells treated with either SP600125 (JNK inhibitor) or SR59230 (ADRB3
inhibitor).
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A.

B.

C.

D.

E.

F.

G.

Figure 26. Downstream signaling of ADRB3. A. Relative BDNF
expression in norepinephrine stimulated SKOV3 cells treated with U0126,
U73122, LY294002 B. Relative BDNF expression in norepinephrine
stimulated SKOV3 cells treated with SB203580. C. H‐Ras siRNA
knockdown efficiency. D. K‐Ras siRNA knockdown efficiency. E Relative
BDNF expression in norepinephrine stimulated SKOV3 cells treated with
H‐Ras siRNA. F. Relative BDNF expression in norepinephrine stimulated
SKOV3 cells treated with K‐Ras siRNA. G. Relative BDNF expression in
norepinephrine stimulated SKOV3 cells treated with GGTI or API‐2.
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Figure 27. Mechanism of norepinephrine stimulated BDNF
expression

83

Discussion

84

1. Summary (Figure 28)
In this dissertation, I have considered the impact that chronic stress may
have on promoting neo‐innervation of tumors and the effects of increased tumor
innervations on tumor growth, as well as the mechanisms by which tumor cells
stimulate nerve growth. Using both human and animal models I have demonstrated
that chronic stress is capable of promoting neo‐innervation of tumors through
upregulation of BDNF gene expression activated by β3 adrenergic signaling and
that this increased nerve density is responsible for promoting tumor growth by
releasing high levels of catecholamines into the tumor tissue. Specifically, after
demonstrating that increased nerve density was associated with poorer outcome in
ovarian cancer patients, I verified that ovarian cancer cells secrete neurotrophic
factors and are capable of inducing neurite outgrowth.

Stimulation of cells

increased production of BDNF as well as promotion of neurite extension. Inibition
of BDNF using siRNA abrogated this effect. I also found that NE‐induced BDNF gene
expression is mediated through ADRB3 activation of cAMP/PKA signaling through
Epac.

Based on in vitro evidence that BDNF is critical to stress‐induced increases
in neurite extension, I next examined human clinical samples for BDNF and found a
positive correlation between BDNF expression, increased nerve density, and overall
poorer outcome. I next utilized a mouse orthotopic model of ovarian cancer and
found that chronic stress increased nerve density in tumors taken from chronically
stressed animals, and that this increase was a result of both neurogenesis and
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Figure 28. Overview model. Following a stressor, catecholamines are released
which then bind to the β3 adrenergic receptor on the tumor cell surface to initiate
downstream signaling through cAMP and Epac. Activated Jun crosses the nuclear
membrane to initiate transcription of BDNF gene expression. BDNF protein is
produced and secreted from the cell where it binds TrkB receptors on sympathetic
nerve endings. This activates growth and proliferation of neurons, increasing nerve
density within the tumor. Increased nerve density results in higher catecholamine
levels, resulting in a positive feedback loop in which nerves promote growth of the
tumor through catecholamines, and tumor cells produce BDNF to support growth
and survival of neurons.
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axonogenesis. In vivo inhibition of BDNF abrogated chronic stress effects on tumor
growth and nerve density. Using adrenalectomized models and in vivo
administration of hexamethonium I demonstrated that chronic stress effects on
tumor growth are mediated through sympathetic nerve endings, as opposed to
systemic release of catecholamines from the adrenal gland, or by central nervous
system control.

hTrkB and mTrkB siRNA demonstrated that BDNF acts in a

paracrine manner, stimulating nerve growth into tumors which, in turn, exert
effects on tumor progression, rather than in an autocrine manner of self‐activation
of TrkB signaling on the tumor cells themselves. Taken together this work is the
first to demonstrate stress‐induced neurogenesis in tumors as well as the
mechanism by which tumors may stimulate tumor neo‐innervation.

2. Future Directions

A. TrkB Switch Kinase mouse model
In this work I have demonstrated a link between increased BDNF production
by tumor cells and increased neo‐innervation. Other studies have suggested that
BDNF signaling may promote tumor growth in an autocrine fashion by activating
TrkB receptors on the tumor cells. I utilized both human and mouse TrkB targeting
siRNA to demonstrate that the growth advantage provided by this autocrine
signaling is insignificant when compared to paracrine effects through increased
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nerve density. However, further studies may be necessary to draw definitive
conclusions on this effect.

Due to the post‐natal lethality of complete TrkB

knockout, one model that may provide further insight into this mechanism is the
TrkB SwitchKinase mouse model available from Taconic Farms (Hudson, NY). This
model provides pure TrkB inhibition by inhibiting kinase function with a dietary
additive that binds to genetically modified TrkB receptor. This is due to point
mutations in the ATP‐binding pocket of the kinase. Interestingly, this system is
inducible and reversible, providing effective knockout of TrkB function without
mortality of the animal (136). This model would extend our findings and provide
support for our findings that, under conditions of chronic stress, BDNF exerts its
effects through recruitment of nerves rather than signaling on tumor cells.

B. Other neurotrophic factors
In this study my primary focus was on the role of BDNF in promoting neo‐
innervation of tumors. However, other neurotrophic factors could also be playing a
role. My preliminary studies that led us to choose BDNF were based on the critical
role that NGF family members play in promoting growth and survival of neurons as
well as the increase in gene expression following NE stimulation. I therefore did
not consider the role that other neurotrophins may be playing in promoting neo‐
innervation of tumors at a basal level. Other groups and I have demonstrated that
various types of tumor cells express numerous neurotrophins (130), however the
role they play is, as yet, undetermined.
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C. Other Neurotransmitters
Additional studies should also examine additional factors that nerves may
be secreting that influence tumor progression. The work done in our lab has thus
far focused primarily on the role of Norepinephrine in promoting tumor growth.
Other groups have demonstrated an anti‐tumorigenic role of dopamine (137).
Neurons are capable of secreting several other factors which may influence tumor
growth. For example, Substance P is well‐known to be involved in anxiety and
depression, and is responsible for controlling many aspects of inflammation and
immunity (138‐140). Additionally, several types of tumors express NK receptors,
which bind Substance P (141‐143). Binding of Substance P to NK receptors on
tumor cells promotes cellular proliferation and metastasis (144). Acetylcholine,
another neurotransmitter secreted by nerve endings, is also known to promote
tumor growth (145). Its receptors are also found on many types of tumor cells, and
may promote angiogenesis and epithelial to mesenchymal transition of tumor cells,
a step associated with increased metastatic potential (146). Conversely, Dopamine,
oxytocin, and GABA (gamma‐amino butyric Acid) all have anti‐tumorigenic effects.
These are just a few of the factors nerves secrete that are known to affect tumor
biology. In this study these factors were not considered, and future work should be
done to examine their role in tumor neo‐innervation.
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D. Immune impact
In my experiments I used an athymic nude mouse model, with the exception
of the adrenalectomized mouse model. These animals are immuno‐deficient, and
allowed me to eliminate the effects that the immune system may have in promoting
or blocking tumor neo‐innervation. While this allowed me to effectively study the
role of stress and increased BDNF without the confounding addition of the various
aspects of immunity, it also begs the question of what role these cells may be
playing. For example, cells of the immune system produce high levels of pro‐
inflammatory cytokines such as IL‐6, which can also act as a neurotrophic factor,
promoting nerve growth and directional guidance (147‐149).

E. Other models of chronic stress
Our lab and many other groups study the effects of chronic stress use the
well‐accepted restraint stress model of chronic stress. This model has been shown
to affect behavior, immunity, endocrine function, neurological, and developmental
processes. It causes activation of many pathways known to be involved in stress
response systems, and is therefore a widely used and accepted model. There are,
however, many other models of stress. Some groups utilize dozens of stressors,
from cold, heat, and isolation, to swim, fear, and predator stress. Effects of these
various stressors have yet to be studied in the context of tumor progression.
Additionally, animals may adapt to repetitive administration of the same stressor,
blunting the effects that may be seen if a different, randomized stressor were used
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each day, and the time during which stress took place varied. Our studies have
shown that stressing animals for a period greater than 3 weeks provides no further
significant increase in tumor burden. Variations in stressors may in fact prove
chronic stress can have much more substantial effects on tumor growth than
current research has described.

F. Types of neurons found in tumors
In addition to the studies outlined here, several other aspects of this study
may benefit from further investigation. For example, although the neurons
identified were shown to be catecholaminergic, we have not yet investigated what
type of neurons they are beyond this distinction. Neurons of the sympathetic
nervous system can be afferent (sensory) or efferent (motor). Cancer patients
frequently mention pain in the area of their tumor. While this could be due to the
pressure put on surrounding tissues by a tumor, it may also indicate that some
neurons within tumors may be sensory. This also begs the question of whether
nerves in the tumors may be influencing CNS biology. Neuronal signals travel both
to and from the CNS. Signals from the tumor may be capable of altering brain
function and processes. By comparing brain regions of tumor‐ and non tumor‐
bearing animals we may be able to determine chemical or structure changes
influenced by tumors.
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G. Origin of neuronal precursors
My studies also demonstrated the presence of neuronal precursors in
tumors. These exciting data suggest that neurogenesis may be taking place in
developing tumors, in addition to axonogenesis of existing neurons. One question
that remains to be answered, however, is from where these neuronal precursors
are recruited. In adults, neural progenitor cells are thought to exist only within the
CNS and bone marrow (150). As neural progenitors in the CNS are primarily
located in the hippocampus and have only been shown to migrate to 5 mm through
the Rostral migratory stream, it is unlikely that neurons in the tumor originate in
the CNS. To provide an answer on whether these cells may be coming from the
bone marrow, our group is using a fluorescent mouse model. These animals are
C57/B6 mice which express RFP protein. The animals were irradiated and bone
marrow transplants were done with marrow taken from GFP expressing donor
mice. This model allows us to differentiate between native cells from the host
mouse and cells derived from the bone marrow.

Analysis will use IHC co‐

localization studies. Tumors will be analyzed for expression of neurofilament
(nerve marker) or doublecortin (neuronal precursor marker) as well as GFP and
RFP protein. Co‐localization between either neurofilament or doublecortin and
RFP would signify neurons originate from the host animal, most likely through
axonogenesis

of

existing

neurons.

Conversely,

co‐localization

between

neurofilament or doublecortin and GFP would represent neurons developing from
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bone marrow‐derived progenitor cells, and would be, to our knowledge, the first
evidence of adult neurogenesis taking place outside of the CNS.

3. Study impact in Cancer
This work provides a mechanistic link between observation that
catecholamines are significantly increased locally in tumor tissue following chronic
stress and how tumors are responsible for promoting this increase. Over the last
several years there has been increasing interest into clinical impacts of chronic
stress and potential treatment options.

As previously mentioned, several

epidemiological studies have shown that β‐blockers may be a viable treatment
option to improve patient care. Other groups are investigating the impact of
psychological intervention and have demonstrated that this may also improve
patient outcome. This work demonstrates the critical role that BDNF plays in
promoting chronic stress effects on tumor progression. It therefore may serve as a
viable target for improving patient outcome.

4. Study impact in other diseases
Chronic stress has long been associated with increased risk of
cardiovascular disease. Several studies exist showing a correlation between
sympathetic innervation and heart disease. Long QT syndrome has long been seen
as a cause of sudden cardiac death and cardiovascular abnormalities (151). In
patients for whom β‐blockers are insufficient treatment, left cardiac sympathetic
denervation is used to improve patient performance (151). Increased nerve density
in various regions of the heart has been associated with several types of
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arrhythmias (152). Experiments in dogs have demonstrated that dogs with atrial
fibrillations have increased nerve density and sprouting in cardiac tissue (153).
Increased cardiac nerve density has also been associated with poor or lacking
recovery following

myocardial infarctions (154).

These studies suggest that

innervation may also play a critical role in stress‐promoted cardiovascular disease.

In humans, bowel tissues are some of the most highly innervated tissues in the
body. This is largely a result of the high amount of control the parasympathetic
nervous system has in controlling gut motility. Chronic stress has also been known
to cause gastric diseases such as irritable bowel syndrome (IBS) (155). One study
demonstrated that patients with IBS have increased nerve density in their colonic
mucosa layer. Additionally, BDNF production is increased in the bowel of IBS
patients (156). Taken together, these data suggest that BDNF expression may be
important in promoting innervation in diseases besides cancer.
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